When CEO Michael Pearson of Valeant Pharmaceuticals International Inc. said in April that "the Middle East and North Africa [together] is going to be a great market," he might have been predicting his firm's $800 million takeover of Amoun Pharmaceutical Co. S.A.E., Egypt's biggest pharma firm, with a powerful presence in the region. Read More
SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a biotech that seeks to bring Western innovation to Chinese patients who have few if any treatment options. Read More
LONDON – A phase I trial has established proof of mechanism for an antibody/small-molecule combination therapy for treating the rare disease systemic amyloidosis, and provided a clear demonstration that it is possible to break down amyloid plaques in humans. Read More
LONDON – Autifony Therapeutics Ltd. has raised £8 million (US$12.5 million) as an extension to its series A, enabling it to add a new indication for its lead hearing disorder drug, to expand into central nervous system disorders and to investigate new applications for its ion channel platform. Read More
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its erstwhile parent. Read More
Redhill Biopharma Ltd., of Tel Aviv, Israel, said it priced a public offering of about 2.4 million American depositary shares (ADSs), each representing 10 of its ordinary shares, at an offering price of $16.25 apiece. Read More
Cellecta Inc., of Mountain View, Calif., said it received a Phase I Small Business Innovative Research grant from the NIH to further its CRISPR-mediated genome-editing program. Read More
Recro Pharma Inc., of Malvern, Pa., reported phase II data showing that acute pain candidate Dex-IN, its intranasal formulation of dexmedetomidine, met the primary endpoint in demonstrating significant pain relief compared with placebo over 48 hours. Read More
